JP2017537893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537893A5 JP2017537893A5 JP2017523295A JP2017523295A JP2017537893A5 JP 2017537893 A5 JP2017537893 A5 JP 2017537893A5 JP 2017523295 A JP2017523295 A JP 2017523295A JP 2017523295 A JP2017523295 A JP 2017523295A JP 2017537893 A5 JP2017537893 A5 JP 2017537893A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- adc
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 53
- 239000000824 cytostatic agent Substances 0.000 claims description 14
- 231100000433 cytotoxic Toxicity 0.000 claims description 14
- 239000002254 cytotoxic agent Substances 0.000 claims description 14
- 230000001472 cytotoxic effect Effects 0.000 claims description 14
- 108010044540 auristatin Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000007452 Plasmacytoma Diseases 0.000 claims description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000033014 Plasma cell tumor Diseases 0.000 claims description 4
- 239000000611 antibody drug conjugate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960000688 pomalidomide Drugs 0.000 claims description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 2
- 108010059074 monomethylauristatin F Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004137 elotuzumab Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073824P | 2014-10-31 | 2014-10-31 | |
| US62/073,824 | 2014-10-31 | ||
| PCT/US2015/058389 WO2016070089A2 (en) | 2014-10-31 | 2015-10-30 | Anti-cs1 antibodies and antibody drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040783A Division JP2020111583A (ja) | 2014-10-31 | 2020-03-10 | 抗ｃｓ１抗体および抗体薬結合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537893A JP2017537893A (ja) | 2017-12-21 |
| JP2017537893A5 true JP2017537893A5 (enExample) | 2018-07-26 |
Family
ID=54478286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523295A Withdrawn JP2017537893A (ja) | 2014-10-31 | 2015-10-30 | 抗ｃｓ１抗体および抗体薬結合体 |
| JP2020040783A Pending JP2020111583A (ja) | 2014-10-31 | 2020-03-10 | 抗ｃｓ１抗体および抗体薬結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020040783A Pending JP2020111583A (ja) | 2014-10-31 | 2020-03-10 | 抗ｃｓ１抗体および抗体薬結合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10011657B2 (enExample) |
| EP (1) | EP3212668B1 (enExample) |
| JP (2) | JP2017537893A (enExample) |
| AU (1) | AU2015339012B2 (enExample) |
| BR (1) | BR112017008945A2 (enExample) |
| CA (1) | CA2966005C (enExample) |
| ES (1) | ES2832711T3 (enExample) |
| IL (1) | IL251938A0 (enExample) |
| SG (1) | SG11201703446RA (enExample) |
| WO (1) | WO2016070089A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| WO2016067035A1 (en) | 2014-10-29 | 2016-05-06 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| CN107949425A (zh) * | 2015-06-29 | 2018-04-20 | 百时美施贵宝公司 | 用于治疗癌症的包含泊马度胺和抗cs1抗体的免疫治疗给药方案 |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| IL306104A (en) | 2016-09-14 | 2023-11-01 | Abbvie Biotherapeutics Inc | Antibodies against (CD27) PD-1 |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| EP3577138A1 (en) * | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| US11124579B2 (en) | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| CN111183147B (zh) | 2017-08-04 | 2024-07-05 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| WO2019030223A1 (en) | 2017-08-07 | 2019-02-14 | Nbe-Therapeutics Ag | ANTHRACYCLINE ANTIBODY-MEDICINAL CONJUGATES HAVING HIGH IN VIVO TOLERABILITY |
| EA202090922A1 (ru) * | 2017-11-29 | 2021-03-09 | Маджента Терапьютикс, Инк. | Композиции и способы истощения cd2+ клеток |
| EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| CN111001012A (zh) * | 2018-10-19 | 2020-04-14 | 四川百利药业有限责任公司 | 一种亲水碳酸酯型抗体偶联药物 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021212638A1 (en) * | 2020-06-19 | 2021-10-28 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of a cell-binding molecule with camptothecin analogs |
| CN116348476A (zh) * | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| JP7454110B2 (ja) * | 2020-12-04 | 2024-03-21 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その中間体、製造方法及び使用 |
| JP7561279B2 (ja) * | 2020-12-18 | 2024-10-03 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｔｒｏｐ２を標的とする抗体薬物複合体、その製造方法及び使用 |
| US20240058463A1 (en) * | 2020-12-18 | 2024-02-22 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| CN113181373B (zh) * | 2021-05-10 | 2024-03-01 | 深圳安特生物医药科技有限公司 | 一种抗体药物偶联制剂及其制备方法和应用 |
| JP2024521092A (ja) * | 2021-05-19 | 2024-05-28 | バイオヘイブン・セラピューティクス・リミテッド | 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート |
| CA3237590A1 (en) | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US136841A (en) | 1873-03-18 | Improvement in cotton-presses | ||
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| US20080025989A1 (en) * | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| WO2006113909A2 (en) | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| ES2649550T3 (es) | 2005-07-18 | 2018-01-12 | Seattle Genetics, Inc. | Conjugados del enlazador fármaco de beta-glucurónido |
| CN101415679A (zh) | 2006-02-02 | 2009-04-22 | 辛塔佳有限公司 | 水溶性cc-1065类似物及其缀合物 |
| MX2009001440A (es) | 2006-08-07 | 2009-04-15 | Pdl Biopharma Inc | Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple. |
| PT2641601T (pt) | 2006-08-07 | 2016-10-14 | Dana Farber Cancer Inst Inc | Métodos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em huluc63 com bortezomib |
| US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| US8399512B2 (en) | 2007-11-28 | 2013-03-19 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| TW201039846A (en) | 2009-04-01 | 2010-11-16 | Genentech Inc | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
| WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| EP3693394A1 (en) | 2011-05-27 | 2020-08-12 | Glaxo Group Limited | Antigen binding proteins |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| CA2837840C (en) | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US20130224228A1 (en) | 2011-12-05 | 2013-08-29 | Igenica, Inc. | Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods |
| KR20140121827A (ko) | 2011-12-23 | 2014-10-16 | 메르사나 테라퓨틱스, 인코포레이티드 | 퓨마질린 유도체-phf 결합체의 약제학적 제형 |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014008375A1 (en) | 2012-07-05 | 2014-01-09 | Mersana Therapeutics, Inc. | Terminally modified polymers and conjugates thereof |
| NO2760138T3 (enExample) * | 2012-10-01 | 2018-08-04 | ||
| WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
| AU2013364043B2 (en) | 2012-12-21 | 2018-01-04 | Seagen Inc. | Anti-NTB-A antibodies and related compositions and methods |
| US9498532B2 (en) * | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
-
2015
- 2015-10-30 AU AU2015339012A patent/AU2015339012B2/en not_active Ceased
- 2015-10-30 BR BR112017008945A patent/BR112017008945A2/pt not_active IP Right Cessation
- 2015-10-30 JP JP2017523295A patent/JP2017537893A/ja not_active Withdrawn
- 2015-10-30 SG SG11201703446RA patent/SG11201703446RA/en unknown
- 2015-10-30 WO PCT/US2015/058389 patent/WO2016070089A2/en not_active Ceased
- 2015-10-30 EP EP15791213.0A patent/EP3212668B1/en active Active
- 2015-10-30 US US14/928,738 patent/US10011657B2/en active Active
- 2015-10-30 CA CA2966005A patent/CA2966005C/en active Active
- 2015-10-30 ES ES15791213T patent/ES2832711T3/es active Active
-
2017
- 2017-04-26 IL IL251938A patent/IL251938A0/en unknown
- 2017-11-21 US US15/819,153 patent/US10308713B2/en active Active
-
2020
- 2020-03-10 JP JP2020040783A patent/JP2020111583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537893A5 (enExample) | ||
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| CN106029083B (zh) | 亲水性抗体-药物偶联物 | |
| JP2023082096A (ja) | エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法 | |
| JP2023071996A (ja) | 多剤抗体薬物コンジュゲート | |
| TW202010498A (zh) | 喜樹鹼肽結合物 | |
| CN115990269B (zh) | 依沙替康衍生物及其连接子-负载物和缀合物 | |
| KR102329024B1 (ko) | 키네신 스핀들 단백질(ksp)과의 항체 약물 접합체 (adcs) | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| KR20200099123A (ko) | 생체활성 접합체, 이의 제조 방법 및 용도 | |
| US11071788B2 (en) | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies | |
| JP2019532056A5 (enExample) | ||
| JP2023520930A (ja) | 電荷多様性リンカー | |
| JP2020509027A5 (enExample) | ||
| EA038512B1 (ru) | Конъюгаты майтанзиноидов и их терапевтическое применение | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| AU2016232839A1 (en) | CD48 antibodies and conjugates thereof | |
| JP6936399B2 (ja) | 抗ｓｅｚ６抗体薬物コンジュゲート及び使用方法 | |
| JP2025505809A (ja) | 抗体－エリブリン又はその誘導体の複合体、その中間体、製造方法、医薬組成物及び使用 | |
| CN120826405A (zh) | 具有靶向作用的偶联物及其制备方法和用途 | |
| CN120923577A (zh) | 大环类药物偶联物及其制备方法和用途 | |
| WO2026011073A1 (en) | Antibody drug conjugates | |
| CN120957758A (zh) | 大环化合物及其制备方法和用途 | |
| HK40097386A (zh) | 多药抗体药物偶联物 |